Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity.

Area of Science:

• Medicinal Chemistry
• Cancer Research
• Drug Development

Background:

• Platinum-based chemotherapy remains a cornerstone in cancer treatment.
• Developing novel platinum complexes with improved selectivity and reduced toxicity is crucial.
• Platinum(IV) prodrugs offer potential for targeted activation via reduction.

Purpose of the Study:

• To synthesize and evaluate the anticancer activity and chemical reactivity of novel platinum(IV) complexes.
• To investigate the mechanism of action, including cellular uptake and protein expression changes.
• To assess the potential of these complexes against various cancer cell lines, including cisplatin-resistant ones.

Main Methods:

• Cytotoxicity screening across 10 cancer cell lines and HEK-293 cells.
• NMR spectroscopy to monitor reactivity with biological reductants.
• Platinum uptake studies in adherent and suspension cell cultures.
• Proteome profiling to analyze apoptosis-related protein expression.

Main Results:

• Monosubstituted Pt(IV) complex exhibited low IC50 values (50-70 nM) against leukemia and cisplatin-resistant cell lines.
• Bis-substituted complex showed minimal toxicity to adherent cells but high cytotoxicity against multidrug-resistant derivatives.
• Reactivity with biological reductants and platinum uptake were confirmed.
• Proteome profiling revealed changes in apoptosis-related proteins.

Conclusions:

• The monosubstituted Pt(IV) complex demonstrates significant anticancer potential, particularly for leukemia and resistant cancers.
• The bis-substituted complex's limited toxicity to adherent cells may be due to cytoskeletal entrapment.
• These findings highlight the potential of tailored Pt(IV) complexes for targeted cancer therapy.